scholarly journals Panitumumab-Induced Paronychia: A Case Report and a Brief Review of the Literature

2020 ◽  
pp. 1-4
Author(s):  
Ahu Yorulmaz ◽  
Basak Yalcin
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Literature Search ◽  
Adverse Reactions ◽  
Growth Factor Receptor ◽  
Chemotherapeutic Agents ◽  
Metastatic Colon Cancer ◽  
Review Of The Literature ◽  
Epidermal Growth ◽  
Underlying Mechanisms

Panitumumab is a recombinant, fully humanized IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Panitumumab is indicated for patients with metastatic colorectal cancer with progressive refractory disease. Targeted therapies are well known to be well tolerated; however, they may induce toxicities that are distinct from those of classical chemotherapeutic agents. For instance, EGFR inhibitors (EGFRIs) are associated with some specific dermatological adverse effects, one of which is nail toxicity. Since panitumumab is fully humanized, unlike most of the other EGFRIs, it has been reported to have reduced incidence of adverse reactions. Nail-related adverse effects are frequently observed with EGFRIs. A literature search has yielded a list of reviews describing panitumumab-induced nail toxicity. However, as far as we know, there is no case report detailing this adverse effect of panitumumab. Here, we present a case of panitumumab-induced paronychia in a 60-year-old woman with metastatic colon cancer. With this case report, we would like to review the literature and discuss the possible underlying mechanisms of this condition.

A case of aseptic meningitis in a cetuximab-experienced patient with metastatic colon cancer

2017 ◽  
Vol 24 (8) ◽  
pp. 632-633 ◽  
Author(s):  
Chelsea L Rohrer ◽  
Zunilda Grullon ◽  
Sarah K George ◽  
Raul Castillo ◽  
Kelli Karasiewicz
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Colon Cancer ◽  
Case Report ◽  
Aseptic Meningitis ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Metastatic Colon Cancer ◽  
Small Cell Lung ◽  
Epidermal Growth

Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is used in the treatment of head and neck cancer, non-small cell lung cancer, and colorectal cancer. This case report describes a rare (<1% incidence) side effect of cetuximab administration: aseptic meningitis. We report a case which is, to our knowledge, the only case at the time of submission of this manuscript of aseptic meningitis in a patient being treated for metastatic colon cancer who was not cetuximab-naïve. This case report may help inform clinicians about the identification and outcome of this adverse event.

scholarly journals Accidental Ixazomib Overdose in a Patient With Multiple Myeloma

2021 ◽  
Vol 9 ◽  
pp. 232470962110132
Author(s):  
Parth J. Sampat ◽  
Maneesh Bisen ◽  
Nimisha Srivastava ◽  
Suman Rao ◽  
Teresa Gentile
Keyword(s):  
United States ◽  
Multiple Myeloma ◽  
Case Report ◽  
Adverse Effects ◽  
Proteasome Inhibitor ◽  
Adverse Reactions ◽  
Hematological Malignancy ◽  
The United States ◽  
Chemotherapeutic Agents ◽  
To Come

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the management of multiple myeloma has made it easier for patients who do not have to come to the hospital for chemotherapy infusions. However, many barriers are associated with oral chemotherapy, and one of them is a misinterpretation of instruction which can have deleterious effects. In this case report, we present a case of a 69-year-old male with multiple myeloma who accidentally took ixazomib daily for 3 days instead of the weekly regimen and thus coming into the hospital with an overdose. In this report, we focus on the adverse effects associated with ixazomib toxicity and how to manage the adverse reactions. Although there is no antidote available for ixazomib, supportive care is very essential in these patients.

Sign in / Sign up

Export Citation Format

Share Document